Companies / Other
AstraZeneca
Pharmaceutical company that licenses de-identified patient data from Tempus AI, including for a foundation model built with Pathos AI. Recorded here: 2 public prices.
astrazeneca.comLatest record 17 Apr 2025
Public prices involving AstraZeneca
- A comprehensive de-identified multimodal oncology dataset (clinical, molecular and imaging records) licensed by Tempus AI to Pathos AI to train a foundational oncology model for AstraZeneca, three-year licence
A realised licence in the licensor's filing; the number of records is not stated. Pathos may pay up to half the fees in its own Series D preferred stock, Tempus pays Pathos $35 million for its commitments and AstraZeneca pays Tempus a separate $35 million fee for the model, so the net cash to the data holder is below $200 million. Tempus's 10-K for 2025 confirms the $50 million upfront was paid. Tempus and Pathos share leadership (the October 2026 Pathos neurology licence at $100 a record is the same pair).
The payer's own page, Tempus AI, Inc. Form 8-K of 23 April 2025, Item 8.01 (SEC)
data license fees of $200 million over a three-year period, including an upfront payment of $50 milliontotal data licence fees over a three-year term
- AstraZeneca's minimum spend commitment to Tempus AI for licensed de-identified data and related services under their master services agreement, non-exclusive, November 2021 to December 2026
A floor across data licences and services at discounted prices, which AstraZeneca may raise to $320 million through December 2028; separate from the $200 million Pathos data licence for the AstraZeneca foundation model.
The payer's own page, Tempus AI, Inc. Form 10-K for 2025 (SEC), AstraZeneca master services agreement
a minimum of $220 millionminimum total spend over the term, data and services together
Cite this
AIData.Broker, “AstraZeneca in the AI training data market”, reviewed 17 Apr 2025. https://aidata.broker/companies/astrazeneca
Free to reuse under CC BY 4.0 if you credit AIData.Broker and link to this page. Each row names the publication that stated it, and words quoted from a source keep that source's own terms.